{"id":"capecitabine-placebo-combined-with-toripalimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (from toripalimab)"}]},"_chembl":{"chemblId":"CHEMBL4297843","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T13:28:33.865377","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is a fluoropyrimidine carbamate that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in rapidly dividing cancer cells. Toripalimab is a humanized monoclonal antibody targeting PD-1 on T cells, blocking the PD-1/PD-L1 interaction to enhance anti-tumor immunity. The combination leverages both direct cytotoxic chemotherapy and immune checkpoint inhibition.","oneSentence":"Capecitabine is a prodrug chemotherapy that converts to fluorouracil to inhibit thymidylate synthase, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:53.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric or gastroesophageal junction cancer (Phase 3 trial indication)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT07191405","phase":"NA","title":"Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-18","conditions":"Immunotherapy, Chemotherapy","enrollment":156},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT05869227","phase":"PHASE3","title":"Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"XIANG YANQUN","startDate":"2023-04-28","conditions":"Nasopharyngeal Carcinoma, Maintenance Therapy","enrollment":166}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Capecitabine/Placebo combined with toripalimab","genericName":"Capecitabine/Placebo combined with toripalimab","companyName":"XIANG YANQUN","companyId":"xiang-yanqun","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug chemotherapy that converts to fluorouracil to inhibit thymidylate synthase, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses. Used for Gastric or gastroesophageal junction cancer (Phase 3 trial indication).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}